216 results on '"Oldenburg J"'
Search Results
2. Fibrinogen Bonn (p. Arg510Cys) in the Aα-Chain Is Associated with High Risk of Venous Thrombosis
3. Physical activity, bone mineral density, and lean mass in patients with haemophilia
4. In-detail AFM analysis of the different conformational states of full-length coagulation Factor VIII and FVIII-vWF complex.
5. The miRNAs present in LSECs play pivotal role in defining their cellular identity and have an impact on the regulation of F8 gene expression
6. Emicizumab Prophylaxis for the Treatment of Infants with Severe Haemophilia A without Factor VIII Inhibitors: Primary Analysis of the HAVEN 7 Study
7. Real-world use of rIX-FP in patients with haemophilia B: Interim results from a prospective, non-interventional study in Germany
8. Molecular, structural, and functional insights into the interaction of coagulation factor VIII with hemorrhage-derived heme
9. Change in Hemophilia Joint Health Score (HJHS) During the Phase 3 XTEND-1 Study of Efanesoctocog Alfa in Patients With Severe Hemophilia A
10. Staphylococcus aureus infection restimulates inhibitor production in tolerized hemophilia A mice
11. An update on real-world use of rVIII‑SingleChain in patients with haemophilia A in Germany: Interim results from a prospective, non-interventional study
12. Lonoctocog alfa vs. octocog alfa: incremental recovery and extended coagulation analysis
13. Detection and domain characterization of anti-FVIII antibodies: Comparative evaluation of NBA and immunoassays
14. New inSight Joint Health tool: Focusing on long-term joint health
15. Activated Protein C Formation on Endothelial Cells is Impaired in Hereditary Protein C Deficiency Independent of the Type of Protein C Gene Mutation and Residual Activity
16. Detection and quantification of heme and hemoglobin for diagnosis of intravascular hemolysis
17. Differences in plasma levels of free thrombin and APC in patients with splanchnic vein thrombosis with and without myeloproliferative neoplasms
18. Investigating the Role of GABARAP in FVIII Trafficking: A Comparative Study of Cellular Responses to Pathway Disturbances
19. Effects of heat treatment on emicizumab and an alternative approach to eliminate interfering FVIII activity prior to functional analysis
20. Emicizumab for the treatment of acquired hemophilia A – consensus recommendations from the GTH-AHA working group
21. Impact of Next Generation Sequencing on molecular genetic analysis in patients with multiple coagulation factor deficiencies
22. HEM-POWR study: Fourth interim analysis evaluating real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Germany
23. Insights into the differential role of GABARAPs proteins at the proteomic level
24. Bleeding phenotype according to factor level in 825 children with non-severe hemophilia; data from the PedNet cohort
25. Impact of Telemedicine Tools on Record Keeping and Compliance in Haemophilia Care
26. Therapie des Antiphosphoplidsyndrom (APS) mit DOAK
27. The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH
28. Influenza infections destabilize established immune tolerance in HemA mice
29. Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study
30. Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis
31. In-vitro and In-silico characterization of a pathogenic variant in integrin β3 associated with hereditary macrothrombocytopenia
32. Digital joint discovery tool to support hemophilia patient education
33. Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B
34. Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study
35. Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A
36. HEM-POWR study: Subgroup analysis evaluating the real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Germany
37. Low resolution cryo-EM maps and AFM analysis combined with alpha fold model of full-length coagulation Factor VIII sheds light on the conformational positioning of the Factor VIII B domain
38. EMIIL - Non-interventional study to investigate the effectiveness of Emicizumab under real-world conditions in pediatric, adolescent, adult and elderly patients with hemophilia A (PwHA) with and without FVIII inhibitors: an interim analysis
39. Analyzing secretion-based patterns of the heterozygous species of coagulation Factor XIII B cysteine mutations reported from mild FXIII deficiency using confocal microscopy
40. An improved understanding of native coagulation factor XIII complex structure using cryo-EM
41. Pain in patients with hereditary bleeding disorders: evaluation of a survey among people affected in Germany
42. Evaluation of the protein C pathway in critically ill patients with severe COVID-19 as compared to bacterial sepsis
43. Correlation between coagulation factor residual activities and detection rate of diseasecausing variants in Rare Bleeding Disorders
44. The effects of single and combined knockouts of GABARAPs proteins family on FVIII secretion
45. Patient-reported symptoms to predict intra-articular location of joint bleeds
46. Real-world experience on the use of rIX-FP in patients with hemophilia B: interim results from a prospective, non-interventional study in Germany
47. Establishment and specification analysis of LSEC-like endothelial cells for the detection of endogenous FVIII
48. Intrinsic difference in cellular response between full-length and B-domain deleted FVIII HEK293 secreting cells: implication for gene therapy
49. Preanalytical quenching of FVIII using FVIII-inhibitors improves the specificity of functional emicizumab testing
50. A snapshot analysis of a prospective, non-interventional study to evaluate real-life prophylactic treatment schedules of factor VIII concentrates
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.